Welcome to our dedicated page for ALUMIS SEC filings (Ticker: ALMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alumis Inc. filings document material events for a Nasdaq-listed biopharmaceutical issuer, including 8-K reports on clinical data, corporate presentations, operating and financial results and capital-structure activity. The disclosures identify common stock listed under ALMS on The Nasdaq Global Select Market and note the company’s emerging growth company status.
The filing record covers envudeucitinib presentations and press releases, financial-results exhibits, common-stock offering disclosures, and shareholder voting matters from the annual meeting and proxy process. These documents frame the company’s governance, material agreements, capital structure and clinical or regulatory disclosure around its TYK2 inhibitor pipeline.
ALUMIS INC. Chief Legal Officer Sanam Pangali exercised stock options for 5,000 shares of common stock at $5.06 per share and sold 5,000 shares in an open-market transaction at $28.00 per share on July 6, 2026.
Following these transactions, Pangali directly owns 11,111 shares of Alumis common stock. The exercised options were granted under the company’s 2024 Equity Incentive Plan, with vesting tied to the executive’s continued service.
ALUMIS INC. director Lynn A. Tetrault reported receiving new equity awards consisting of restricted stock units and stock options. The filing shows a grant of 3,553 shares of common stock through RSUs at no cash cost and a stock option covering 15,528 shares with a fixed exercise price of $28.14 per share.
Both the RSUs and the option are scheduled to vest on the first anniversary of the grant date, and in any event will be fully vested by the issuer’s 2027 annual stockholder meeting, subject to her continuous service under the company’s 2024 Equity Incentive Plan. The awards will also vest in full upon a qualifying change in control if continuous service is maintained through that date.
ALUMIS INC. director Yao Zhengbin reported equity compensation grants, acquiring both restricted stock units and stock options rather than making any open‑market trades. He received 3,553 shares of Common Stock as a restricted stock unit (RSU) award at no cash cost.
He also received a stock option covering 15,528 shares of Common Stock at an exercise price of $28.14 per share, expiring on June 29, 2036. After the grants, he directly holds 27,082 Common shares. Both the RSUs and options vest on the first anniversary of the grant date, and will in any case be fully vested by the issuer’s 2027 annual stockholder meeting, with accelerated vesting upon a qualifying Change in Control, all subject to his continuous service under the company’s 2024 Equity Incentive Plan.
ALUMIS INC. director Sapna Srivastava received equity-based compensation in the form of restricted stock units and stock options. She was granted 3,553 shares of common stock issuable upon settlement of RSUs and an option covering 15,528 shares of common stock at an exercise price of $28.14 per share.
Both the RSUs and the option shares vest on the first anniversary of the grant date, and in any case will be fully vested on the date of the issuer's 2027 annual stockholder meeting, subject to her continuous service under the company’s 2024 Equity Incentive Plan. They will also vest in full upon a Change in Control, again subject to continuous service.
ALUMIS INC. director Patrick Machado reported new equity awards and his updated holdings. He received a grant of 3,553 shares of common stock as a restricted stock unit (RSU) award at no cost, which will vest on the first anniversary of the grant date or, in any case, by the company’s 2027 annual stockholder meeting, subject to continuous service or earlier vesting upon a Change in Control under the 2024 Equity Incentive Plan. He was also granted stock options for 15,528 shares of common stock at an exercise price of $28.14 per share, with the same vesting conditions. Following these awards, he holds 3,553 common shares directly and 7,064 common shares indirectly through the Patrick Machado Revocable Trust, where he serves as trustee, plus the newly granted options.
Alumis Inc. director Srinivas Akkaraju reported new equity awards and updated fund holdings. He received a grant of 3,553 shares of common stock in the form of restricted stock units, plus stock options covering 15,528 shares at an exercise price of $28.14 per share. Both the RSUs and options vest on the first anniversary of the grant date, and in any event are fully vested by the issuer's 2027 annual stockholder meeting, subject to his continuous service and with full vesting upon a qualifying change in control.
After these grants, he directly holds 3,553 shares and options on 15,528 shares, and is associated with indirect holdings of 1,853,488 shares through Samsara Opportunity Fund, L.P. and 4,491,731 shares through Samsara BioCapital, L.P. The fund positions are held by those partnerships, with Akkaraju’s beneficial interest limited to his pecuniary stake.
Alumis Inc. shareholder update: AyurMaya Capital Management Company, L.P. and David E. Goel report beneficial ownership of 15,139,707 shares of Alumis common stock, representing 12.3% of the class. This percentage is based on 123,432,027 voting common shares outstanding as of May 5, 2026.
The amendment states that the change in ownership percentage results solely from a change in Alumis’s shares outstanding, not from new share purchases or sales. The reporting persons have shared voting and dispositive power over all reported shares and confirm no transactions in Alumis stock during the past 60 days.
Alumis Inc. held its 2026 Annual Meeting of Stockholders on June 30, 2026. As of the May 5, 2026 record date, 123,432,072 shares of voting common stock were outstanding and entitled to vote.
Stockholders elected James B. Tananbaum, Lynn Tetrault and Zhengbin (Bing) Yao as Class II directors to serve until the 2029 Annual Meeting of Stockholders. Stockholders also ratified the Audit Committee’s appointment of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026, with 105,924,017 votes for, 283,113 against and 242,002 abstentions.
Alumis Inc. furnished an updated corporate presentation for investors, analysts, and other stakeholders. The presentation, dated June 2026, is available on the company’s website and attached as Exhibit 99.1.
The material is furnished, not filed, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.